AbCellera Biologics Inc. ABCL
11.49 USD -0.13 (-1.12%)
At closeNov 13, 2026, 7:59 PM EST
11.52 +0.03 +0.26%
After hours · Nov 13, 7:59 PM ET
11.06 Day range 11.83
2.75 52-week range 15.02
- YTD
- +235.96%
- 1 year
- +217.40%
News
seekingalpha.com AbCellera Biologics Inc. (ABCL) Presents at Stifel 2026 Healthcare Conference 2026 Transcript AbCellera Biologics Inc. ( ABCL ) Stifel 2026 Healthcare Conference 2026 November 10, 2026 7:00 PM EST Company Participants Carl L. Hansen - CEO, President & Chairperson Conference Call Participants…
zacks.com Are Medical Stocks Lagging ABCELLERA BIOLG (ABCL) This Year? Here is how AbCellera Biologics Inc. (ABCL) and Editas Medicine (EDIT) have performed compared to their sector so far this year.
marketbeat.com AbCellera Biologics Eyes Phase 3 for Hot-Flash Drug After Promising Midstage Results AbCellera Biologics NASDAQ: ABCL is preparing to advance its experimental hot-flash treatment ABCL635 into late-stage development next year after a midstage study produced stronger-than-expected…
benzinga.com StoneX Maintains Buy on AbCellera Biologics, Raises Price Target to $15 StoneX analyst Robert Wasserman maintains AbCellera Biologics (NASDAQ:ABCL) with a Buy and raises the price target from $11 to $15.
benzinga.com Stifel Maintains Buy on AbCellera Biologics, Raises Price Target to $14 Stifel analyst Stephen Willey maintains AbCellera Biologics (NASDAQ:ABCL) with a Buy and raises the price target from $9 to $14.
seekingalpha.com AbCellera Biologics Inc. (ABCL) Q3 2026 Earnings Call Transcript AbCellera Biologics Inc. (ABCL) Q3 2026 Earnings Call Transcript
marketbeat.com What AbCellera Biologics (ABCL) Said on Its Q3 Earnings Call AbCellera Biologics NASDAQ: ABCL plans to advance its experimental hot flash treatment ABCL635 into late-stage development in 2027 after reporting positive mid-stage results, while shelving further…
zacks.com AbCellera Biologics Inc. (ABCL) Reports Q3 Loss, Tops Revenue Estimates AbCellera Biologics Inc. (ABCL) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of a loss of $0.18. This compares to a loss of $0.19 per share a year ago.
benzinga.com AbCellera Biologics Q3 2026 Earnings Call Transcript AbCellera Biologics (NASDAQ:ABCL) reported third-quarter financial results on Monday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought…- benzinga.com AbCellera Biologics Q3 EPS $(0.13) Beats $(0.16) Estimate, Sales $10.639M Beat $8.416M Estimate AbCellera Biologics (NASDAQ:ABCL) reported quarterly losses of $(0.13) per share which beat the analyst consensus estimate of $(0.16) by 18.75 percent. This is a 31.58 percent increase over losses of…
businesswire.com AbCellera Reports Q3 2026 Business Results VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera Reports Q3 2026 Business Results.
benzinga.com UBS Initiates Coverage On AbCellera Biologics with Buy Rating, Announces Price Target of $18 UBS analyst Alice Nettleton initiates coverage on AbCellera Biologics (NASDAQ:ABCL) with a Buy rating and announces Price Target of $18.
businesswire.com AbCellera Announces Presentation of Phase 1/2 Data for ABCL635 at TMS 2026 Annual Meeting VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera Announces Presentation of Phase 1/2 Data for ABCL635 at TMS 2026 Annual Meeting.
businesswire.com AbCellera to Report Third Quarter 2026 Financial Results on November 9, 2026 VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera to Report Third Quarter 2026 Financial Results on November 9, 2026.
defenseworld.net AbCellera Biologics Inc. (NASDAQ:ABCL) Receives Consensus Rating of “Moderate Buy” from Analysts AbCellera Biologics Inc. (NASDAQ: ABCL - Get Free Report) has received a consensus rating of "Moderate Buy" from the nine research firms that are currently covering the firm, Marketbeat Ratings…
benzinga.com JP Morgan Initiates Coverage On AbCellera Biologics with Overweight Rating, Announces Price Target of $17 JP Morgan analyst Brian Cheng initiates coverage on AbCellera Biologics (NASDAQ:ABCL) with a Overweight rating and announces Price Target of $17.- benzinga.com Goldman Sachs Reinstates Neutral on AbCellera Biologics, Announces $13 Price Target Goldman Sachs analyst Andrea Newkirk reinstates AbCellera Biologics (NASDAQ:ABCL) with a Neutral and announces $13 price target.
zacks.com ABCL Stock Surges 121% in 3 Months: Here's What You Need to Know AbCellera shares skyrocket 121% as positive ABCL635 data, major partnerships and a stronger financial position boost investor confidence.- benzinga.com AbCellera To Present Phase 2 Data On ABCL635 At IMS 20th World Congress On Menopause AbCellera (NASDAQ:ABCL) today announced an upcoming oral presentation of Phase 2 data on ABCL635 at the International Menopause Society (IMS) 20th World Congress on Menopause, to be held September 30…
businesswire.com AbCellera Announces Presentation of Phase 2 Data for ABCL635 at the IMS World Congress on Menopause 2026 VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera Announces Presentation of Phase 2 Data for ABCL635 at the IMS World Congress on Menopause 2026.
businesswire.com AbCellera to Present at the Cantor Global Healthcare Conference on September 9, 2026 VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera to Present at the Cantor Global Healthcare Conference on September 9, 2026.
defenseworld.net BlackRock Inc. Makes New Investment in AbCellera Biologics Inc. $ABCL BlackRock Inc. purchased a new position in shares of AbCellera Biologics Inc. (NASDAQ: ABCL) during the second quarter, according to the company in its most recent disclosure with the Securities and…
benzinga.com What'sGoing On With AbCellera Biologics Stock On Tuesday? AbCellera Biologics Inc. (NASDAQ:ABCL) stock is trading higher on Tuesday. Year-to-date, the stock has jumped over 250%.
benzinga.com What'sGoing On With AbCellera Biologics Stock On Tuesday? AbCellera Biologics stock gains as investors react to Jazz Pharmaceuticals’ FDA approval and the companies’ antibody partnership.
benzinga.com Nayax, Immatics, Moderna, Marvell Technology And Other Big Stocks Moving Higher On Tuesday Nasdaq: NYAX rose 13.9% on Tuesday after announcing acquisition of IPS Group Inc. for $350 million. Other big gainers include CAPR, RZLV, CRML, and MAIR.
seekingalpha.com Are Biotech Stocks The 'Comeback Kid' Of 2026? I Say Yes Biotech, especially small-cap names, is experiencing renewed optimism as macro and policy headwinds subside, driving sector-wide rallies. Stabilization at the FDA and a resurgence in M&A and IPO…
businesswire.com AbCellera Announces Pricing of Oversubscribed $200 Million Public Offering of Common Shares and Pre-Funded Warrants VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera Announces Pricing of Oversubscribed $200 Million Public Offering of Common Shares and Pre-Funded Warrants.
benzinga.com What's Going on With AbCellera Biologics Stock On Wednesday? AbCellera Biologics Inc. (NASDAQ:ABCL) shares are trading higher on Wednesday following the announcement of positive Phase 2 clinical trial results for ABCL635, a single-dose treatment aimed at…
benzinga.com What's Going on With AbCellera Biologics Stock On Wednesday? AbCellera shares rise after positive ABCL635 Phase 2 results, while bullish momentum and analyst price targets point to further upside.
benzinga.com National CineMedia Posts Downbeat Q2 Results, Joins Borr Drilling, AbCellera Biologics And Other Big Stocks Moving Lower In Wednesday’s Pre-Market Session U.S. stock futures higher, Nasdaq 100 up 150 pts. National CineMedia shares down 16.4% on weak Q2 results and Captivate Holdings acquisition. Other stocks also falling in pre-market trading.- benzinga.com AbCellera Biologics Commences Underwritten Public Offering Of $200M Of Its Common Shares AbCellera Biologics Inc. (NASDAQ:ABCL) ("AbCellera") today announced that it has commenced an underwritten public offering of $200.0 million of its common shares and, in lieu of common shares to…
businesswire.com AbCellera Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants.- benzinga.com Truist Securities Maintains Buy on AbCellera Biologics, Raises Price Target to $30 Truist Securities analyst Robyn Kamaus maintains AbCellera Biologics (NASDAQ:ABCL) with a Buy and raises the price target from $12 to $30.
defenseworld.net Investors Buy Large Volume of AbCellera Biologics Call Options (NASDAQ:ABCL) AbCellera Biologics Inc. (NASDAQ: ABCL - Get Free Report) was the target of unusually large options trading on Monday. Stock investors purchased 16,666 call options on the company. This is an…
benzinga.com AbCellera Biologics Menopause Drug Data Shows 'New Efficacy Benchmark' AbCellera reports positive Phase 2 clinical trial results for ABCL635, a single-dose treatment for menopausal hot flashes.
benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session Gainers Jin Medical International (NASDAQ:ZJYL) shares rose 58.1% to $3.4 during Monday's regular session. The market value of their outstanding shares is at $16.8 million. As per the press release,…
benzinga.com Varex Imaging Posts Upbeat Q3 Earnings, Joins Bowman Consulting, MarineMax And Other Big Stocks Moving Higher On Monday BWMN gained 55.1%, HZO rose 45.8%, ABCL gained 35.6%, SLN rose 34.3%, ACHR gained 19.5%, NESR gained 16.4%, AQST gained 15.4%, STDN rose 13.7%.
benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session Gainers Jin Medical International (NASDAQ:ZJYL) stock rose 70.7% to $3.67 during Monday's pre-market session. The company's market cap stands at $16.8 million. As per the news, the H1 earnings report…- benzinga.com AbCellera’s ABCL635 Meets Primary Endpoints In Phase 2 Vasomotor Symptom Study Phase 2 results showed best-in-class reductions in both frequency and severity of moderate-to-severe vasomotor symptoms after a single doseABCL635 significantly improved sleep and patient global…
benzinga.com Market-Moving News for August 10th BKYI: -8% | BIO-key And Visualforma Win Contract To Strengthen Digital Identity Security For Portuguese National Security Agency ABCL: 24% | AbCellera Reports Phase 2 Trial Results Showing…- benzinga.com AbCellera Reports Phase 2 Trial Results Showing Significant Symptom Reduction, Improved Sleep, And Favorable Tolerability For ABCL635 Phase 2 results showed best-in-class reductions in both frequency and severity of moderate-to-severe vasomotor symptoms after a single doseABCL635 significantly improved sleep and patient global…
- benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session Gainers AbCellera Biologics (NASDAQ:ABCL) shares increased by 8.2% to $7.5 during Friday's after-market session. The company's market cap stands at $1.9 billion. As per the news, the Q2 earnings…
- benzinga.com AbCellera To Release Top-Line Data From Phase 2 Trial Evaluating ABCL635 For Treatment Of Moderate-To-Severe Vasomotor Symptoms Due To Menopause On August 10 Management to host a conference call and live webcast at 4:30 a.m. PT / 7:30 a.m. ETAbCellera (NASDAQ:ABCL) will release top-line data from its Phase 2 trial evaluating ABCL635 for the treatment of…
- benzinga.com Stifel Maintains Buy on AbCellera Biologics, Raises Price Target to $9 Stifel analyst Stephen Willey maintains AbCellera Biologics (NASDAQ:ABCL) with a Buy and raises the price target from $8 to $9.
benzinga.com Cantor Fitzgerald Maintains Overweight on AbCellera Biologics, Raises Price Target to $12 Cantor Fitzgerald analyst Steve Seedhouse maintains AbCellera Biologics (NASDAQ:ABCL) with a Overweight and raises the price target from $11 to $12.- benzinga.com AbCellera Biologics Q2 EPS $(0.18) Misses $(0.14) Estimate, Sales $4.050M Miss $7.784M Estimate AbCellera Biologics (NASDAQ:ABCL) reported quarterly losses of $(0.18) per share which missed the analyst consensus estimate of $(0.14) by 28.57 percent. This is a 50 percent decrease over losses of…
- benzinga.com Benchmark Upgrades AbCellera Biologics to Buy, Announces $11 Price Target Benchmark analyst Robert Wasserman upgrades AbCellera Biologics (NASDAQ:ABCL) from Hold to Buy and announces $11 price target.
benzinga.com Jazz Pharmaceuticals Gains Oncology Firepower Through AbCellera Collaboration Jazz Pharmaceuticals teams with AbCellera on cancer therapies as analysts maintain positive targets despite a recent Zepzelca trial setback.- benzinga.com Jazz Pharma And AbCellera Announce Preclinical Research Collaboration, Option And License Agreement To Discover, Develop Next-Gen T-Cell Engaging Multispecific Antibodies The collaboration includes $56 million in upfront payments to AbCellera and up to $792 million in potential option fees and milestone payments for any program Jazz exercises its option to developJazz…
benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session